LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 1 of total 1

Search options

Article ; Online: Predictors of intracranial hemorrhage in patients with atrial fibrillation treated with oral anticoagulants: Insights from the GARFIELD-AF and ORBIT-AF registries.

Lim, Toon Wei / Camm, Alan John / Virdone, Saverio / Singer, Daniel E / Bassand, Jean P / Fonarow, Gregg C / Fox, Keith A A / Ezekowitz, Michael / Gersh, Bernard J / Kayani, Gloria / Hylek, Elaine M / Kakkar, Ajay K / Mahaffey, Kenneth W / Pieper, Karen S / Peterson, Eric D / Piccini, Jonathan P

Clinical cardiology

2023  Volume 46, Issue 11, Page(s) 1398–1407

Abstract: Background: An unmet need exists to reliably predict the risk of intracranial hemorrhage (ICH) in patients with atrial fibrillation (AF) treated with oral anticoagulants (OACs).: Hypothesis: An externally validated model improves ICH risk ... ...

Abstract Background: An unmet need exists to reliably predict the risk of intracranial hemorrhage (ICH) in patients with atrial fibrillation (AF) treated with oral anticoagulants (OACs).
Hypothesis: An externally validated model improves ICH risk stratification.
Methods: Independent factors associated with ICH were identified by Cox proportional hazard modeling, using pooled data from the GARFIELD-AF (Global Anticoagulant Registry in the FIELD-Atrial Fibrillation) and ORBIT-AF (Outcomes Registry for Better Informed Treatment of Atrial Fibrillation) registries. A predictive model was developed and validated by bootstrap sampling and by independent data from the Danish National Patient Register.
Results: In the combined training data set, 284 of 53 878 anticoagulated patients had ICH over a 2-year period (0.31 per 100 person-years; 95% confidence interval [CI]: 0.28-0.35). Independent predictors of ICH included: older age, prior stroke or transient ischemic attack, concomitant antiplatelet (AP) use, and moderate-to-severe chronic kidney disease (CKD). Vitamin K antagonists (VKAs) were associated with a significantly higher risk of ICH compared with non-VKA oral anticoagulants (NOACs) (adjusted hazard ratio: 1.61; 95% CI: 1.25-2.08; p = .0002). The ability of the model to discriminate individuals in the training set with and without ICH was fair (optimism-corrected C-statistic: 0.68; 95% CI: 0.65-0.71) and outperformed three previously published methods. Calibration between predicted and observed ICH probabilities was good in both training and validation data sets.
Conclusions: Age, prior ischemic events, concomitant AP therapy, and CKD were important risk factors for ICH in anticoagulated AF patients. Moreover, ICH was more frequent in patients receiving VKA compared to NOAC. The new validated model is a step toward mitigating this potentially lethal complication.
MeSH term(s) Humans ; Anticoagulants ; Atrial Fibrillation/complications ; Atrial Fibrillation/diagnosis ; Atrial Fibrillation/drug therapy ; Administration, Oral ; Intracranial Hemorrhages/chemically induced ; Intracranial Hemorrhages/diagnosis ; Intracranial Hemorrhages/epidemiology ; Stroke/etiology ; Risk Factors ; Registries ; Renal Insufficiency, Chronic/complications ; Vitamin K
Chemical Substances Anticoagulants ; Vitamin K (12001-79-5)
Language English
Publishing date 2023-08-18
Publishing country United States
Document type Journal Article
ZDB-ID 391935-3
ISSN 1932-8737 ; 0160-9289
ISSN (online) 1932-8737
ISSN 0160-9289
DOI 10.1002/clc.24109
Shelf mark
Zs.A 1423: Show issues Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (1.OG)
ab Jg. 2022: Lesesaal (EG)
Database MEDical Literature Analysis and Retrieval System OnLINE

More links

Kategorien

To top